Building a safer pipeline of therapeutics for pain management
Antibe Therapeutics has surmounted the main barrier to safer treatment of pain and inflammation
Article content
Antibe Therapeutics Inc. (TSXV: ATE) is one of this year’s Venture 50 companies — as a healthcare company, Antibe is engaged in building a pipeline of safer, non-addictive therapeutics for pain and inflammation.
Antibe’s drug pipeline targets large markets in non-addictive pain management. The company’s lead drug, now in late Phase 2B trials, has demonstrated unprecedented safety in the treatment of chronic pain, a condition that affects hundreds of millions of people worldwide.
The 2020 Venture 50 is a ranking of top performers on TSX Venture Exchange over the last year. The ranking is comprised of 10 companies from each of the five industry sectors, and they were selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume.
For the full 2020 Venture 50 ranking, methodology and profile videos of companies included in the ranking, visit: www.tsx.com/venture50
This story was provided by Market One Media Group for commercial purposes.
